Skip to main content

Table 2 Summary of adverse events in the safety analysis set

From: Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial

  Lanthanum carbonate (n = 23) Placebo (n = 12)
  n (%) Events n (%) Events
Any adverse event 7 (30.4) 15 2 (16.7) 3
  Related to investigational product 2 (8.7) 6 1 (8.3) 1
Moderate or severe adverse event 2 (8.7) 4
Serious adverse event 2 (8.7) 4
  Related to investigational product
  Leading to withdrawal of investigational product 1 (4.3) 1
Type of adverse event       
Gastrointestinal disorders 4 (17.4) 4 2 (16.7) 3
  Abdominal discomfort 1 (8.3) 1
  Constipation 2 (8.7) 2
  Diarrhea 1 (8.3) 1
  Dry mouth 1 (4.3) 1
  Acute pancreatitis 1 (4.3) 1
  Vomiting 1 (8.3) 1
Cardiac disorders 1 (4.3) 3
  Cardiac failure 1 (4.3) 2
  Myocardial infarction 1 (4.3) 1
Other organ system classes       
  Thirst 1 (4.3) 1
  Bronchitis 1 (4.3) 1
  Anorexia 1 (4.3) 1
  Headache 1 (4.3) 1
  Polyuria 1 (4.3) 1
  Erythema 1 (4.3) 1
  Hyperhidrosis 1 (4.3) 1
  Hypertension 1 (4.3) 1
\